David A. Siegel Silverback Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 24,300 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,300Holding current value
$0% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding SBTX
# of Institutions
122Shares Held
61.4MCall Options Held
1.37MPut Options Held
83.8K-
Deerfield Management Company, L.P. (Series C) New York, NY11.1MShares$00.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA9.24MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
About Silverback Therapeutics, Inc.
- Ticker SBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,473,800
- Description
- Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...